Bone DB, Hammond JR. Nucleoside and nucleobase transporters of primary human cardiac microvascular endothelial cells: characterization of a novel nucleobase transporter.
H]hypoxanthine was accumulated within hMVECs (Km ϭ 96 Ϯ 37 M; V max ϭ 1.6 Ϯ 0.3 pmol ⅐ l Ϫ1 ⅐ s Ϫ1 ) despite the lack of a known nucleobase transport system. This novel transporter was dipyridamole-insensitive but could be inhibited by adenine (K i ϭ 19 Ϯ 7 M) and other purine nucleobases, including chemotherapeutic analogs. A variety of other cell types also expressed the nucleobase transporter, including the nucleoside transporter-deficient PK(15) cell line (PK15NTD). Further characterization of [ 3 H]hypoxanthine uptake in the PK15NTD cells showed no dependence on Na ϩ or H ϩ . PK15NTD cells expressing human ENT2 accumulated 4.5-fold more [ 3 H]hypoxanthine in the presence of the ENT2 inhibitor dipyridamole than did PK15NTD cells or hMVECs, suggesting trapping of ENT2-permeable metabolites. Understanding the nucleoside and nucleobase transporter profiles in the vasculature will allow for further study into their roles in pathophysiological conditions such as hypoxia or ischemia.
adenosine; hypoxanthine; human; cardiovascular THE TRANSMEMBRANE FLUX OF hydrophilic nucleosides and nucleobases is mediated by integral membrane proteins, including equilibrative nucleoside transporters (SLC29; ENTs) and concentrative nucleoside transporters (SLC28; CNTs) (3, 14) . These nucleoside transporters (NTs) have roles in salvaging endogenous nucleosides, such as adenosine, and have been exploited for cancer chemotherapy and treatments for viral infection (17) . The CNTs are Na ϩ -dependent transporters that facilitate movement of nucleosides against their concentration gradient. Three members of the CNT family have been cloned, each with distinct substrate specificity. CNT1 transports adenosine and pyrimidine nucleosides, CNT2 transports purine nucleosides and uridine, and CNT3 is broadly selective for both purine and pyrimidine nucleosides (22) . The ENTs, on the other hand, are Na ϩ -independent facilitative diffusion transporters that rely on the concentration gradient of the substrate and thus are capable of mediating both influx and efflux of nucleosides. The two classical ENTs have been identified as being sensitive (ENT1) or insensitive (ENT2) to the nucleoside analog nitrobenzylmercaptopurine riboside (NBMPR) (28) . ENT2 is also able to transport nucleobases like hypoxanthine (21) . Recently, two more ENT family members have been identified: ENT3 is associated with intracellular acidic environments (15) , and ENT4 was initially discovered as a monoamine transporter in the brain (12) .
The purine nucleoside adenosine is an important compound in the vasculature. Acting through a variety of G-proteincoupled receptors, adenosine mediates physiological actions such as, among others, vasodilation, bradycardia, and inhibition of platelet aggregation (27) . NTs play a role in regulating adenosine levels in the vasculature by facilitating its removal from the extracellular environment (19) . In fact, cardiovascular drugs like dipyridamole inhibit NTs, thereby extending the lifespan of adenosine in the vasculature (25) . Analogs of NBMPR (29) and dipyridamole (18) are now being designed and tested for the potential to act as cardioprotective agents, thus highlighting the importance of vascular NTs as potential therapeutic targets.
Investigations of NTs in the vasculature widely utilize models derived from the macrovasculature, with a particular focus on umbilical vein endothelial cells. However, the majority of exchange between the blood and peripheral tissues occurs in the microvasculature, in which microvascular endothelial cells (MVECs) are responsible for the regulation of this exchange. It has been shown that endothelial cells in the heart are responsible for the uptake of up to 65% of free adenosine (9) . Therefore, changes in the ability of MVECs to transport or metabolize adenosine can have profound effects on the cardiovasculature and surrounding tissues.
Here, we describe the nucleoside and nucleobase transport capabilities of primary human cardiac MVECs.
Moravek Biochemicals (Brea, CA). Nonradiolabeled 2-chloroadenosine, hypoxanthine, NBMPR, nitrobenzylthioguanine riboside, dipyridamole {2,6-bis(diethanolamino)-4,8-dipiperidinopyrimido- [5,4-d] pyrimidine}, and all other nucleosides and nucleobases were obtained from Sigma-Aldrich (St. Louis, MO). Dilazep {N,NЈ-bis [3-(3,4,5-trimethoxybenzoyloxy) propyl] homopiperazine} was from Asta Werke (Frankfurt, Germany), and draflazine {2-(aminocarbonyl)-4-amino-2,6-dichlorophenyl-4-[5,5-bis(4-fluorophenyl)-pentyl]-1-piperazineacetamide 2HCl} was provided by Janssen Research Foundation (Beerse, Belgium).
Cell culture. Primary human cardiac MVECs were purchased from Cambrex Bioscience or Lonza (Walkersville, MD) and were cultured as per manufacturer's instructions. Cells were supplied at passage 3 and used between passage 4 and 7. All assays were conducted with cells from the same lot (subject was a 4-year-old female). No morphological changes occurred during culture up to passage 7. Quality assurance from the manufacturer verified the isolation as pure endothelial cells using immunohistologic staining for the presence of acetylated LDL and von Willebrand's (factor VIII) antigen and the absence of smooth muscle ␣-actin. Some studies required the use of additional cell types, and all media and culture reagents were from Invitrogen (Burlington, ON). Primary rat MVECs were isolated as previously described (2) and cultured in M199 medium containing 10% FBS, 100 U/ml penicillin G, 100 g/ml streptomycin sulfate, 0.25 g/ml amphotericin B, 2 mM L-glutamine, 0.025 U/ml heparin, and 75 g/ml endothelial cell growth supplement. Nucleoside transporter-deficient PK(15) cell line (PK15NTD) and PK15NTD-human ENT2 cells were a generous gift from Dr. Ming Tse (Johns Hopkins University) and were cultured in MEM containing 10% bovine growth serum with penicillin G (100 U/ml), streptomycin sulfate (100 mg/ ml), nonessential amino acids (0.1 mM), and sodium pyruvate (1 mM). G418 (300 g/ml) was added to the culture medium of the PK15NTD-human ENT2 cells to maintain a selection pressure on the stable transfection. UMR-108 and HEK-293 cells were a gift from Dr. Peter Chidiac (Department of Physiology and Pharmacology, University of Western Ontario). UMR-108 cells were cultured in ␣-MEM with 10% FBS, penicillin G (100 U/ml), and streptomycin sulfate (100 mg/ml). HEK-293 cells were cultured in MEM with 10% FBS and 10 g/ml gentamicin. Madin-Darby canine kidney cells were cultured in MEM with 10% FBS and penicillin G (100 U/ml) and streptomycin sulfate (100 g/ml). All cells were maintained in a humidified atmosphere at 37°C with 5% CO2 in T175 culture flasks. For experimental assays, cells were trypsinized (0.05% trypsin-0.53 mM EDTA) and then diluted fourfold in 500 g/ml trypsin inhibitor in PBS (in mM: 137 NaCl, 6.3 Na2HPO4, 2.7 KCl, 1.5 KH2PO4, 0.9 CaCl2 ⅐ 2H2O, 0.5 MgCl2 ⅐ 6H2O; pH 7.4). Cells were collected by centrifugation, and pellets were washed in either PBS or a Na ϩ -free buffer [NMG (in mM): 140 N-methyl-D-glucamine, 5 KCl, 4.2 KH2PO4, 0.36 K2HPO4, 10 HEPES, 1.3 CaCl2 ⅐ 2H2O, and 0.5 MgCl2 ⅐ 6H2O; pH 7.4] and resuspended in the same buffer as required for immediate use. In some cases, cells were depleted of ATP by sequential incubation at 37°C with rotenone and 2-deoxyglucose as described previously (2) .
[ . Incubation of cells with 50 nM NBMPR to block ENT1-mediated uptake resulted in a rate of uptake that was not significantly different from that seen in the presence of 10 M dipyridamole and NBMPR ( Fig. 2A) . Furthermore, when uptake buffer was changed from NMG (ϪNa inhibition curve. K i values derived from these data are listed in Table 1 .
[ 3 H]hypoxanthine uptake. Human cardiac MVECs were able to accumulate [ 3 H]hypoxanthine under Na ϩ -free conditions despite an apparent lack of ENT2 activity. Uptake was insensitive to dipyridamole; however, the addition of 1 mM adenine was able to block uptake (Fig. 4A) . As with 2-[ 3 H]chloroadenosine, Na ϩ had no effect on the uptake of (Fig. 4B) . Consequently, subsequent experiments were performed under ATP-depleted conditions to minimize the effects of intracellular metabolism. With the use of a 15-s time point to estimate initial rate, the V max of [ 3 H]hypoxanthine influx was determined as 1.6 Ϯ 0.3 pmol⅐l Ϫ1 ⅐s Ϫ1 with a K m of 96 Ϯ 37 M (Fig. 4C ). Additional nucleobases were tested for the ability to inhibit 5 M [
3 H]hypoxanthine uptake. Adenine was the most effective, with a K i of 19 Ϯ 7 M. Guanine produced significant inhibition of 17 Ϯ 4% at a concentration of 1 M (Fig. 5A ).
Higher concentrations of guanine could not be achieved because of low solubility in assay buffers at physiological pH. Pyrimidines were much less effective, with thymine producing inhibition only at 1 mM (59 Ϯ 6%) (Fig. 5A) , and cytosine and uracil had no effect at 1 mM concentrations (data not shown).
The chemotherapeutic thiopurine analogs 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) and the pyrimidine analog 5-fluorouracil (5-FU) were also examined. Both 6-MP and 6-TG were able to inhibit 5 M [ 3 H]hypoxanthine uptake with an IC 50 of 37 Ϯ 11 M and 20 Ϯ 2 M, respectively (Fig. 5B) . As with other pyrimidines, 5-FU had no effect on [ 3 H]hypoxanthine uptake (data not shown).
To confirm that the dipyridamole-insensitive hypoxanthine uptake mechanism was nucleobase selective, the nucleosides adenosine and uridine were tested. Adenosine had an extrap- 3 H]chloroadenosine for the times indicated. Some cell lots were preincubated with 100 nM NBMPR to inhibit only equilibrative nucleoside transporter 1 (ENT1). Total uptake (no inhibitors) minus ENT1 inhibited uptake represents ENT2-mediated uptake. Nonmediated uptake was determined with cells preincubated with 10 M NBMPR and 10 M dipyridamole (n ϭ 5). B: concentration-dependent uptake of 2-[ 3 H]chloroadenosine. Cells were incubated with increasing concentrations of 2-[ 3 H]chloroadenosine for 7 s. Transporter-mediated uptake is presented as pmol ⅐ l Ϫ1 ⅐ s Ϫ1 and was defined as total uptake minus nonmediated uptake (n ϭ 4). Table 1 . DY, dipyridamole. olated IC 50 value of 1.3 Ϯ 0.9 mM (Fig. 5A) , and uridine had no effect (data not shown).
Nucleobase transport in other cell types. The identification of Na ϩ -independent [ 3 H]hypoxanthine transport in human cardiac MVECs, by a mechanism other than ENT2, led to the examination of other cell types for evidence of a similar dipyridamole-insensitive nucleobase transport system. Established cell lines from human (U2OS and HEK-293), rat (UMR-108), pig (PK15NTD), and dog (Madin-Darby canine kidney) were examined along with primary rat skeletal muscle MVECs. Figure 6 shows the time course profiles for dipyridamole-insensitive hypoxanthine uptake by these cells. All cells tested displayed evidence of dipyridamole-insensitive nucleobase transport with the exception of HEK-293 cells.
PK15NTD cells were chosen for further characterization of this nucleobase transporter. These cells do not have ENT1 or ENT2 (26), thereby eliminating any contribution from other nucleoside/nucleobase transporters to the results obtained. [ 3 H]hypoxanthine uptake by PK15NTD cells was concentration dependent with a similar K m (122 Ϯ 31 pmol/l) to the human cardiac MVEC in ATP-depleted conditions and a V max of 7.0 Ϯ 0.6 pmol⅐l Ϫ1 ⅐s Ϫ1 (Fig. 7A) . There was no effect of pH on [ [ 3 H]adenine was tested as a transport substrate with unlabeled hypoxanthine as the inhibitor (Fig. 7B ). Hypoxanthine at 150 M was able to produce ϳ20% inhibition of 500 nM [ 3 H]adenine uptake under ATP-depleted conditions. The use of unlabeled 1 mM adenine was required for total inhibition. 3 H]hypoxanthine and indicated purine for 60 s. Uptake in the absence of inhibitor was defined as 100%, and totally inhibited uptake (1 mM adenine) was defined as 0% (n Ն 3). B: inhibition of [ 3 H]hypoxanthine uptake by purine nucleobase analogs. 6-MP, 6-mercaptopurine; 6-TG, 6-thioguanine. Assays were conducted in the same manner as A (n Ն 3) . Ki values are reported in Table 1 . (Fig. 8) .
DISCUSSION
The microvasculature forms a barrier between the circulation and peripheral tissues and is responsible for mediating nutrient exchange between these two compartments. MVEC regulation of nucleosides via NTs can have profound effects on the cardiovascular actions of adenosine, warranting further investigation of NTs as potential therapeutic targets (19) .
Human cardiac MVECs have both high-and low-affinity binding sites for the ENT1-selective probe NBMPR. The K d of the high-affinity site is consistent with reported values for ENT1 (15) . Our group, in rat skeletal muscle MVECs (2), and others (6) have reported the presence of the low-affinity population of NBMPR binding sites, which may be a result of [ 3 H]NBMPR binding to intracellular ENT1 proteins. The highaffinity maximum binding capacity of ϳ53,000 ENT1 sites/ cell likely represents the transporters associated with the plasma membrane.
2-Chloroadenosine is an established substrate of NTs and was chosen to limit the effects of intracellular metabolism on the measurement of transport kinetics (5, 16) . Na ϩ -independent uptake of 2-chloroadenosine in the presence or absence of a low concentration of NBMPR (50 nM) to inhibit ENT1 revealed no significant contribution of the NBMPR-insensitive ENT2 to the overall uptake. In addition, NBMPR, dilazep, draflazine, and dipyridamole all produced monophasic inhibition curves for inhibiting 2-chloroadenosine uptake (pseudo Hill coefficients were approximately Ϫ1) with K i values typical of ENT1 inhibition (28) . Numerous endothelial cell models express a combination of ENT1 and ENT2, including primary rat MVECs (2), human umbilical vein endothelial cells (1), primary mouse MVECs (unpublished data), and EVC 304 cells (21) . In this regard, human cardiac MVECs, which express only ENT1, are an exception.
Although human cardiac MVECs had no functional ENT2, they were still able to accumulate hypoxanthine under Na free conditions. Uptake was insensitive to dipyridamole; however, other purine nucleobases were capable of blocking influx. There was no significant change in uptake in the presence of Na ϩ , thus ruling out the ascorbic acid transport system. An increase in H ϩ had no effect, and uptake was not inhibited by monoamines (data not shown); thus this hypoxanthine transporter is not the recently identified ENT4 (11) . The apparent K m of hypoxanthine uptake (96 Ϯ 37 M) was threefold lower, and the K i of adenine inhibition of hypoxanthine uptake (19 Ϯ 7 M) reported in this study was ϳ140 times lower than previously reported for human ENT2 (21) . Together, these data support that hypoxanthine uptake in human cardiac MVECs was mediated by a transport system distinct from ENT2. Further characterization identified the transport system as purine nucleobase selective. The only pyrimidine that could inhibit hypoxanthine uptake was thymidine at nonphysiological concentrations (Ͼ1 mM). The nucleoside adenosine also inhibited uptake at high concentrations (IC 50 Ͼ 1 mM), but this may be the result of adenosine metabolism releasing adenine. The chemotherapeutic purine nucleobase analogs 6-MP and 6-TG demonstrated an affinity for the nucleobase transport system, whereas the pyrimidine analog 5-FU did not. The K i results of 6-MP and 6-TG inhibition of hypoxanthine uptake (ϳ20 -30 M) are similar to reported values of therapeutic concentrations found within cells (10) . This has relevance in the role that the vasculature plays in delivering chemotherapeutic agents to the intended target such that if this nucleobase transport system is blocked or downregulated the chemotherapeutic purine nucleobase analogs would be less able to gain access to their intracellular site of cytotoxic action.
The ability of a cell to mediate the transmembrane flux of nucleobases is important, as evidenced by the existence of at least two distinct transport systems for nucleobases in many cell types. Regulation of intracellular levels of nucleobases, such as hypoxanthine, may be critical during periods of physiological stress, including hypoxia or ischemia. During hypoxia or ischemia in the heart, the breakdown of ATP in cardiomyocytes results in an increase in adenosine, which is released to the interstitial space via NTs (13) . The surrounding endothelium then accumulates this extracellular adenosine, where it is metabolized to inosine via adenosine deaminase. Subsequent metabolism by purine nucleoside phosphorylase produces hypoxanthine as an intermediate to the final product of uric acid (27) . It is in the production of hypoxanthine that the role of MVEC nucleobase transporters may hold importance. Because hypoxanthine is metabolized to xanthine by xanthine oxidase, reactive oxygen species (ROS) are produced (20) . Links have been established between xanthine oxidase-derived ROS and endothelial dysfunction (4, 24) . Therefore, having a system capable of regulating hypoxanthine levels, before xanthine oxidase-mediated metabolism of hypoxanthine were to occur, may prevent or reduce ROS-induced endothelial dysfunction.
The molecular identity of this distinctive dipyridamoleinsensitive, purine-selective nucleobase transporter is presently not known. Despite this lack of identity, we have named the transporter equilibrative nucleobase transporter 1 (ENBT1). There is some evidence in the literature that similar transporters may exist (23, 26), and we have been able to identify its presence through function in several cell types from various species. Preliminary data from our laboratory have suggested that mouse MVECs are more similar to human cardiac MVECs with respect to their nucleoside and nucleobase transport properties. However, rat MVECs appear to have less of the dipyridamole-insensitive [ 3 H]hypoxanthine transporter and instead express more ENT2 as the primary nucleobase transport system. This needs to be considered when using rat as a model for human extrapolation studies.
Of the cells tested, only HEK-293 cells appeared to be deficient in ENBT1. Thus HEK-293 cells may prove useful to the heterologous expression of candidate genes for ENBT1. In contrast, PK15NTD cells, which lack ENTs, have very high levels of ENBT1. Thus PK15NTD cells may provide a useful model to study dipyridamole-insensitive hypoxanthine transport. The lack of ENTs in these cells allows for the transfection of a NT of interest for the study of interactions between nucleoside and nucleobase transporters, as we have shown with the PK15NTD-human ENT2 cell line.
The 4.5-fold enhancement of hypoxanthine accumulation in the presence of dipyridamole in PK15NTD-human ENT2 cells (see Fig. 8 ) may be the result of intracellular trapping of hypoxanthine metabolites, or perhaps hypoxanthine itself, that normally are substrates for ENT2. It is possible for ENT2-preferring nucleosides, like inosine (28) , to be formed from hypoxanthine by purine nucleoside phosphorylase when normal physiological conditions are changed to allow the enzyme to catalyze the preferred reaction of nucleoside synthesis (7) . Thus nucleobases can be used to replenish depleted nucleoside and nucleotide stores, using ENBT1 as a salvage pathway. Cells that lack ENT2, like human MVECs, or ones that have their existing ENT2 transporters blocked will see an enhancement of this salvage pathway, possibly leading to improved cellular function during periods of physiological stress.
In summary, we have characterized the nucleoside and nucleobase transporters of primary human cardiac MVECs.
Human cardiac MVECs rely solely on ENT1 for nucleoside transport, and we have identified a novel nucleobase transport system, which we have named ENBT1. ENBT1 is present in a variety of different cell types in combination with ENT2; however, this combination varies between species and cell types. We recommend that future studies involving nucleoside or nucleobase regulation in the microvasculature be conducted in mouse models if human models are unavailable. The role of nucleoside and nucleobase transporters in the vasculature is important and complex. Regulation of extracellular adenosine levels, either through ENT expression or pharmacological intervention, will impact cardiovascular function. Considering the vasodilatory effects of adenosine, ENT regulation of purine levels can impact perfusion and thus nutrient exchange between the microvasculature and surrounding tissues (19) . Control of nucleobase levels by ENT2 or ENBT1 will have implications in nutrient salvage, chemotherapy, and ROS production during hypoxia or ischemia.
